176 related articles for article (PubMed ID: 19084272)
21. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m).
Ji SR; Wu Y; Zhu L; Potempa LA; Sheng FL; Lu W; Zhao J
FASEB J; 2007 Jan; 21(1):284-94. PubMed ID: 17116742
[TBL] [Abstract][Full Text] [Related]
22. Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.
Lee RT; Lee YC
Glycobiology; 2003 Jan; 13(1):11-21. PubMed ID: 12634320
[TBL] [Abstract][Full Text] [Related]
23. Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk.
Eisenhardt SU; Habersberger J; Peter K
Trends Cardiovasc Med; 2009 Oct; 19(7):232-7. PubMed ID: 20382347
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line.
Tron K; Manolov DE; Röcker C; Kächele M; Torzewski J; Nienhaus GU
Eur J Immunol; 2008 May; 38(5):1414-22. PubMed ID: 18412163
[TBL] [Abstract][Full Text] [Related]
25. Functional effects of CRP binding to nuclei.
Shephard EG; van Helden PD; Strauss M; Böhm L; De Beer FC
Immunology; 1986 Jul; 58(3):489-94. PubMed ID: 3733149
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov.
Herzberger P; Siegel C; Skerka C; Fingerle V; Schulte-Spechtel U; Wilske B; Brade V; Zipfel PF; Wallich R; Kraiczy P
Int J Med Microbiol; 2009 Feb; 299(2):141-54. PubMed ID: 18706858
[TBL] [Abstract][Full Text] [Related]
27. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence.
Bhakdi S; Torzewski M; Paprotka K; Schmitt S; Barsoom H; Suriyaphol P; Han SR; Lackner KJ; Husmann M
Circulation; 2004 Apr; 109(15):1870-6. PubMed ID: 15037531
[TBL] [Abstract][Full Text] [Related]
28. Binding of C-reactive protein (CRP) by human peripheral blood lymphocytes in vivo.
Lozański G; Pawłowski T; Błazczak P; Wiktorowicz K; Mackiewicz SH
Arch Immunol Ther Exp (Warsz); 1991; 39(3):335-9. PubMed ID: 1810225
[TBL] [Abstract][Full Text] [Related]
29. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction.
Sjöwall C; Wetterö J; Bengtsson T; Askendal A; Almroth G; Skogh T; Tengvall P
Biochem Biophys Res Commun; 2007 Jan; 352(1):251-8. PubMed ID: 17113035
[TBL] [Abstract][Full Text] [Related]
30. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement.
Volanakis JE; Narkates AJ
J Immunol; 1981 May; 126(5):1820-5. PubMed ID: 7217669
[TBL] [Abstract][Full Text] [Related]
31. Binding of C-reactive protein to human lymphocytes. II. Interaction with a subset of cells bearing the Fc receptor.
James K; Hansen B; Gewurz H
J Immunol; 1981 Dec; 127(6):2545-50. PubMed ID: 7028875
[TBL] [Abstract][Full Text] [Related]
32. Binding of C-reactive protein to human lymphocytes. I. Requirement for a binding specificity.
James K; Hansen B; Gewurz H
J Immunol; 1981 Dec; 127(6):2539-44. PubMed ID: 7028874
[TBL] [Abstract][Full Text] [Related]
33. Binding of phospholipase C-related but catalytically inactive protein to phosphatidylinositol 4,5-bisphosphate via the PH domain.
Gao J; Takeuchi H; Zhang Z; Fujii M; Kanematsu T; Hirata M
Cell Signal; 2009 Jul; 21(7):1180-6. PubMed ID: 19298853
[TBL] [Abstract][Full Text] [Related]
34. Polymorphism of structural forms of C-reactive protein.
Wang HW; Wu Y; Chen Y; Sui SF
Int J Mol Med; 2002 Jun; 9(6):665-71. PubMed ID: 12011986
[TBL] [Abstract][Full Text] [Related]
35. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.
Aquilina JA; Robinson CV
Biochem J; 2003 Oct; 375(Pt 2):323-8. PubMed ID: 12892563
[TBL] [Abstract][Full Text] [Related]
36. Decreased migration of myeloid dendritic cells through increased levels of C-reactive protein.
Frenzel H; Pries R; Brocks CP; Jabs WJ; Wittkopf N; Wollenberg B
Anticancer Res; 2007; 27(6B):4111-5. PubMed ID: 18225580
[TBL] [Abstract][Full Text] [Related]
37. Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an
Williams RD; Moran JA; Fryer AA; Littlejohn JR; Williams HM; Greenhough TJ; Shrive AK
Front Immunol; 2020; 11():115. PubMed ID: 32117266
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer.
Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Nakatsu T; Saito H; Minamiya Y; Suzuki T; Ogawa J
J Am Coll Surg; 2009 Oct; 209(4):477-83. PubMed ID: 19801321
[TBL] [Abstract][Full Text] [Related]
39. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP.
Wang MS; Black JC; Knowles MK; Reed SM
Anal Bioanal Chem; 2011 Sep; 401(4):1309-18. PubMed ID: 21725632
[TBL] [Abstract][Full Text] [Related]
40. Immunochemical recognition of the binding of C-reactive protein to solid-phase phosphorylethanolamine.
Coll JM
Rev Esp Fisiol; 1988 Jun; 44(2):169-78. PubMed ID: 3057546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
